Cellectis (NASDAQ: CLLS) reported Q2 EPS of ($0.22), $0.02 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $16 million versus the consensus estimate of $11.03 million.

For earnings history and earnings-related data on Cellectis (CLLS) click here.